Kanichi G. Nakata

Kaiser Permanente Washington Health Research Institute

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system”.

The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07433-4

N/A

0.359DataRank · unranked

7 citations

Kelli O’Connell, Sonia Persaud, Victoria Blinder, Rachael Burganowski, Isaac J. Ergas +18 more

Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019

Breast Cancer Research(2024)10.1186/s13058-024-01822-9

N/A

0DataRank · unranked

11 citations

Kelli O’Connell, Isaac J. Ergas, Marilyn J. Foley, Grace Gallagher, Jennifer J. Griggs +17 more

Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I–IIIA breast cancer

International Journal of Cancer(2024)10.1002/ijc.35053

N/A

0DataRank · unranked

4 citations

Kelli O’Connell, Sonia Persaud, Victoria Blinder, Rachael Burganowski, Isaac J. Ergas +19 more

Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer

Cancer Epidemiology Biomarkers & Prevention(2024)10.1158/1055-9965.epi-24-0360

N/A

0DataRank · unranked

2 citations

Kelli O’Connell, Sonia Persaud, Victoria Blinder, Rachael P. Burganowski-Doud, Isaac J. Ergas +18 more

Provider and facility factors in relation to receipt of dose-reduced chemotherapy among patients with breast cancer.

JCO Oncology Practice(2024)10.1200/op.2024.20.10_suppl.310

N/A

0DataRank · unranked

0 citations

Kelli O’Connell, Jenna Bhimani, Victoria Blinder, Rachael Doud, Grace Gallagher +15 more

Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer

npj Breast Cancer(2025)10.1038/s41523-025-00833-9

N/A

0DataRank · unranked

1 citations

Kelli O’Connell, Grace B Gallagher, Victoria Blinder, Rachael Burganowski, Isaac J. Ergas +19 more

Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf314

N/A

0DataRank · unranked

1 citations

Kelli O’Connell, Jenna Bhimani, Grace Gallagher, Victoria Blinder, Rachael Doud +19 more

The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: Results of a retrospective cohort study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6600

N/A

0DataRank · unranked

0 citations

Kelli O’Connell, Rachael Burganowski, Isaac J. Ergas, Grace B Gallagher, Jennifer J. Griggs +15 more

Evaluation of methods to identify chemotherapy‐related hematologic toxicities in real‐world settings

International Journal of Cancer(2025)10.1002/ijc.70266

N/A

0DataRank · unranked

0 citations

Kelli O’Connell, Jenna Bhimani, Victoria Blinder, Rachael Burganowski, Isaac J. Ergas +20 more